It has been reported that patients with polymerase ε ultra-mutated endometrial carcinomas had better prognosis than patients with polymerase ε-wild type endometrial carcinoma and this phenomenon was linked with the activated CD4+ T cell responses in polymerase ε ultra-mutated endometrial carcinoma patients [23], from which it could be inferred that the enhanced responses of CD4+ T cells might mitigate the malignant development of endometrial carcinoma. This evidence concerns the gene CD4 and endometrial carcinoma.